Please login to the form below

Not currently logged in
Email:
Password:

drug licensing

This page shows the latest drug licensing news and features for those working in and with pharma, biotech and healthcare.

Merck enters agreement with Hanmi for investigational NASH drug

Merck enters agreement with Hanmi for investigational NASH drug

NGM313 is an antibody targeting the beta-Klotho/FGFR1c receptor complex that could represent a new a completely new drug class for NASH and diabetes. ... The drug works by activating FGFR1c signalling, a pathway that appears to have a key role in

Latest news

More from news
Approximately 2 fully matching, plus 62 partially matching documents found.

Latest Intelligence

  • The changing nature of approvals – what does the future hold? The changing nature of approvals – what does the future hold?

    first launched on the world drug market than major companies (those with R&D spend of US$2bn). ... Based on CMR International data, since 2015 we have seen the number of drug commercialisation/licensing deals continue to gradually decline while the

  • ‘Flexible working’: fashionable buzzword or fundamental business operation? ‘Flexible working’: fashionable buzzword or fundamental business operation?

    Externally, there are the usual issues: downward pressure on hourly rates, reduced client budgets, environmental pressures on new drug development and licensing/reimbursement.

  • Charting a course for expansion Charting a course for expansion

    a key licensing agreement and the not inconsequential matter of a management reshuffle. ... Cabometyx accelerates. Earlier this year Ipsen signed another deal to bolster its pipeline by harnessing external innovation, licensing promising cancer drug

  • Pharma deals during January 2013 Pharma deals during January 2013

    Out licensing WW rights to RN 307 antibody (binds to calcitonin related peptide) phase II ready. ... 18-MC (18-methoxycoronaridine) as a treatment for drug addiction, obesity and compulsive behaviour.

  • Modern anticoagulants threaten status quo Modern anticoagulants threaten status quo

    However, Sanofi has since discontinued its development. The company announced in May 2011 that the drug is available for licensing. ... The drug is also in phase III development for the acute treatment of VTE.

More from intelligence
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Ipsen bolsters leadership team Ipsen bolsters leadership team

    Prior to this, she has served as senior vice president, head of global business development at Teva Pharmaceuticals, where she led and executed multiple business development transactions ranging from licensing to ... acquisition of drug candidates,

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Bedrock Group

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics